Skip to main content

Table 1 Baseline characteristics of patients enrolled in this study

From: Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer

Characteristic

Training cohort

Validation cohort

pCR (No, %)

Non-pCR (No, %)

pa

pCR (No, %)

Non-pCR (No, %)

pa

Median age (range)

47 (28–70)

53 (30–66)

0.045

50 (26–72)

50 (27–62)

0.973

T stageb

  

0.234

  

0.108

 T1

6 (10.9)

3 (9.1)

 

7 (31.8)

0 (0)

 

 T2

36 (65.5)

21 (63.6)

9 (40.9)

10 (71.4)

 T3

11 (20)

4 (12.1)

5 (22.7)

3 (21.4)

 T4

2 (3.6)

5 (15.2)

1 (4.6)

1 (7.2)

90

N stageb

  

0.082

  

0.261

 N0

26 (47.3)

11 (33.3)

 

1 (4.5)

3 (21.4)

 

 N1

19 (34.5)

10 (30.3)

20 (90.9)

10 (71.4)

 N2

9 (16.4)

7 (21.2)

0 (0)

0 (0)

 N3

1 (1.8)

5 (15.2)

1 (4.6)

1 (7.2)

Overall stageb

  

0.486

  

0.693

 I

1 (1.8)

1 (3.0)

 

0 (0)

0 (0)

 

 II

37 (67.3)

18 (54.6)

16 (72.7)

11 (78.6)

 III

17 (30.9)

14 (42.4)

6 (17.3)

3 (21.4)

Chemo-IM regimen

  

0.811

  

0.152

NACI regimen

  

0.296

  

1.000

 Nab-pac/Carbo + anti-PD1

21 (38.2)

9 (27.3)

 

0 (0)

0 (0)

 

 EC-TCb + anti-PD1

34 (31.8)

24 (72.7)

 

22 (100)

14 (100)

 

Pathological Gradec

  

0.013

  

0.014

 I–II

16 (29.1)

17 (56.7)

 

1 (4.5)

5 (35.7)

 

 III

39 (70.9)

13 (43.3)

21 (95.5)

9 (64.3)

Median Ki67 (range)

75 (20–95)

62.5 (10–95)

0.024

45 (20–95)

60 (20–90)

0.711

Surgery

  

0.144

  

0.755

 BCS + SLNB

11 (20)

1 (3.0)

 

0 (0)

0 (0)

 

 BCS + ALND

8 (14.5)

7 (21.2)

 

9 (40.9)

5 (35.7)

 

 Mastectomy + SLNB

14 (25.5)

8 (24.2)

 

0 (0)

0 (0)

 

 Mastectomy + ALND

12 (21.8)

10 (30.3)

 

13 (59.1)

9 (64.3)

 

 NSM + SLNB

3 (5.5)

0 (0)

 

0 (0)

0 (0)

 

 NSM + ALND

7 (12.7)

7 (21.2)

 

0 (0)

0 (0)

 
  1. pCR: pathological complete response; non-pCR: non-pathological complete response; Nab-pac: albumin-bound paclitaxel; Carbo: carboplatin; anti-PD-1: Sintilimab or Camrelizumab or Pembrolizumab; EC: epirubicin plus cyclophosphamide; TCb: paclitaxel plus carboplatin; BCS: breast-conserving surgery; SLNB: sentinel lymph node biopsy; ALND: axillary lymph node dissection; NSM: nipple-sparing mastectomy
  2. ap values were calculated by the Chi-square test for categorical variables and student’s t test for continuous variables
  3. bAccording to the 8th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging manual
  4. cThree patients in Guangdong Provincial People's Hospital did not have such data
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us